Comparative Pharmacology
Head-to-head clinical analysis: PYROLITE versus SODIUM IODIDE I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYROLITE versus SODIUM IODIDE I 131.
PYROLITE vs SODIUM IODIDE I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pyrolite is not a recognized pharmaceutical drug. No mechanism of action data available.
Sodium iodide I 131 is a radioactive isotope that emits beta particles and gamma rays. It is taken up by the thyroid gland via the sodium-iodide symporter and incorporated into thyroid hormones. The beta radiation causes local destruction of thyroid tissue, reducing hormone production and treating hyperthyroidism or thyroid cancer.
1000 mg orally every 8 hours for 7 days.
For thyroid ablation or therapy of thyrotoxicosis: 100-200 mCi (3.7-7.4 GBq) orally as a single dose. For diagnostic imaging: 5-10 μCi (0.185-0.37 MBq) orally.
None Documented
None Documented
Terminal half-life: 4.5 hours (range 3.8–5.2). Clinical context: Eliminated rapidly; no accumulation with q6h dosing; dose adjustment needed in CrCl <30 mL/min.
Physical half-life: 8.02 days. Effective half-life in euthyroid patients: ~5-7 days, but reduced to ~3-5 days in hyperthyroidism due to increased turnover. In thyroid cancer with remnant ablation, effective half-life may be longer (up to 8 days) due to reduced clearance.
Renal: 70% unchanged; Fecal: 20% as metabolites; Biliary: 10% as conjugates.
Primarily renal; approximately 90% excreted in urine within 72 hours, with the remainder eliminated via feces (biliary-fecal route, <10% in bile).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical